Increased serum concentrations and surface expression on peripheral white blood cells of decay-accelerating factor (CD55) in patients with active ulcerative colitis

Chiho Makidono, Motowo Mizuno, Junichirou Nasu, Sakiko Hiraoka, Hiroyuki Okada, Kazuhide Yamamoto, Teizo Fujita, Yasushi Shiratori

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Inflammatory stimuli induce expression and release of decay-accelerating factor (DAF), a complement-regulatory protein present on peripheral-blood cells. Therefore, in ulcerativa colitis (UC), an inflammatory colonic disease in which activated leukocytes are involved, DAF may be released from leukocytes into the circulation. In this study we compared serum DAF concentrations and surface DAF expression on peripheral-blood cells in patients with UC with disease activity. Peripheral-blood samples were obtained from 60 patients with UC (30 with active and 30 with inactive disease) and 19 healthy volunteers. Serum DAF concentrations were determined by means of immunoassay, and surface DAF expression on blood cells was examined with the use of flow cytometry. Serum DAF concentrations in patients with active disease (mean 48.6 ng/mL) were significantly higher than those in patients whose disease was in remission (33. 3 ng/mL; P = .0003) and those in healthy controls (32.3 ng/mL; P = .0007). Surface DAF expression on neutrophils, CD14+ monocytes, and subsets of lymphocytes in patients with active UC was significantly increased compared with that in patients with UC in remission and in healthy controls. The increased serum DAF concentrations and surface DAF expression on leukocyte fractions in patients with active disease fell to significantly lower levels when the disease had gone into remission after medical therapy. Serum DAF concentrations are increased in UC patients in relation to disease activity. The likely source of increased DAF concentrations is peripheral-blood leukocytes that have been activated as part of the UC disease process.

Original languageEnglish
Pages (from-to)152-158
Number of pages7
JournalJournal of Laboratory and Clinical Medicine
Volume143
Issue number3
DOIs
Publication statusPublished - Mar 2004
Externally publishedYes

Fingerprint

CD55 Antigens
Ulcerative Colitis
Leukocytes
Blood
Cells
Colitis
Serum
Blood Cells
Colonic Diseases
Lymphocytes
Flow cytometry
Lymphocyte Subsets
Immunoassay

ASJC Scopus subject areas

  • Medicine(all)
  • Pathology and Forensic Medicine

Cite this

Increased serum concentrations and surface expression on peripheral white blood cells of decay-accelerating factor (CD55) in patients with active ulcerative colitis. / Makidono, Chiho; Mizuno, Motowo; Nasu, Junichirou; Hiraoka, Sakiko; Okada, Hiroyuki; Yamamoto, Kazuhide; Fujita, Teizo; Shiratori, Yasushi.

In: Journal of Laboratory and Clinical Medicine, Vol. 143, No. 3, 03.2004, p. 152-158.

Research output: Contribution to journalArticle

@article{49db9883195b4f609aaf9307cd957572,
title = "Increased serum concentrations and surface expression on peripheral white blood cells of decay-accelerating factor (CD55) in patients with active ulcerative colitis",
abstract = "Inflammatory stimuli induce expression and release of decay-accelerating factor (DAF), a complement-regulatory protein present on peripheral-blood cells. Therefore, in ulcerativa colitis (UC), an inflammatory colonic disease in which activated leukocytes are involved, DAF may be released from leukocytes into the circulation. In this study we compared serum DAF concentrations and surface DAF expression on peripheral-blood cells in patients with UC with disease activity. Peripheral-blood samples were obtained from 60 patients with UC (30 with active and 30 with inactive disease) and 19 healthy volunteers. Serum DAF concentrations were determined by means of immunoassay, and surface DAF expression on blood cells was examined with the use of flow cytometry. Serum DAF concentrations in patients with active disease (mean 48.6 ng/mL) were significantly higher than those in patients whose disease was in remission (33. 3 ng/mL; P = .0003) and those in healthy controls (32.3 ng/mL; P = .0007). Surface DAF expression on neutrophils, CD14+ monocytes, and subsets of lymphocytes in patients with active UC was significantly increased compared with that in patients with UC in remission and in healthy controls. The increased serum DAF concentrations and surface DAF expression on leukocyte fractions in patients with active disease fell to significantly lower levels when the disease had gone into remission after medical therapy. Serum DAF concentrations are increased in UC patients in relation to disease activity. The likely source of increased DAF concentrations is peripheral-blood leukocytes that have been activated as part of the UC disease process.",
author = "Chiho Makidono and Motowo Mizuno and Junichirou Nasu and Sakiko Hiraoka and Hiroyuki Okada and Kazuhide Yamamoto and Teizo Fujita and Yasushi Shiratori",
year = "2004",
month = "3",
doi = "10.1016/j.lab.2003.11.004",
language = "English",
volume = "143",
pages = "152--158",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Increased serum concentrations and surface expression on peripheral white blood cells of decay-accelerating factor (CD55) in patients with active ulcerative colitis

AU - Makidono, Chiho

AU - Mizuno, Motowo

AU - Nasu, Junichirou

AU - Hiraoka, Sakiko

AU - Okada, Hiroyuki

AU - Yamamoto, Kazuhide

AU - Fujita, Teizo

AU - Shiratori, Yasushi

PY - 2004/3

Y1 - 2004/3

N2 - Inflammatory stimuli induce expression and release of decay-accelerating factor (DAF), a complement-regulatory protein present on peripheral-blood cells. Therefore, in ulcerativa colitis (UC), an inflammatory colonic disease in which activated leukocytes are involved, DAF may be released from leukocytes into the circulation. In this study we compared serum DAF concentrations and surface DAF expression on peripheral-blood cells in patients with UC with disease activity. Peripheral-blood samples were obtained from 60 patients with UC (30 with active and 30 with inactive disease) and 19 healthy volunteers. Serum DAF concentrations were determined by means of immunoassay, and surface DAF expression on blood cells was examined with the use of flow cytometry. Serum DAF concentrations in patients with active disease (mean 48.6 ng/mL) were significantly higher than those in patients whose disease was in remission (33. 3 ng/mL; P = .0003) and those in healthy controls (32.3 ng/mL; P = .0007). Surface DAF expression on neutrophils, CD14+ monocytes, and subsets of lymphocytes in patients with active UC was significantly increased compared with that in patients with UC in remission and in healthy controls. The increased serum DAF concentrations and surface DAF expression on leukocyte fractions in patients with active disease fell to significantly lower levels when the disease had gone into remission after medical therapy. Serum DAF concentrations are increased in UC patients in relation to disease activity. The likely source of increased DAF concentrations is peripheral-blood leukocytes that have been activated as part of the UC disease process.

AB - Inflammatory stimuli induce expression and release of decay-accelerating factor (DAF), a complement-regulatory protein present on peripheral-blood cells. Therefore, in ulcerativa colitis (UC), an inflammatory colonic disease in which activated leukocytes are involved, DAF may be released from leukocytes into the circulation. In this study we compared serum DAF concentrations and surface DAF expression on peripheral-blood cells in patients with UC with disease activity. Peripheral-blood samples were obtained from 60 patients with UC (30 with active and 30 with inactive disease) and 19 healthy volunteers. Serum DAF concentrations were determined by means of immunoassay, and surface DAF expression on blood cells was examined with the use of flow cytometry. Serum DAF concentrations in patients with active disease (mean 48.6 ng/mL) were significantly higher than those in patients whose disease was in remission (33. 3 ng/mL; P = .0003) and those in healthy controls (32.3 ng/mL; P = .0007). Surface DAF expression on neutrophils, CD14+ monocytes, and subsets of lymphocytes in patients with active UC was significantly increased compared with that in patients with UC in remission and in healthy controls. The increased serum DAF concentrations and surface DAF expression on leukocyte fractions in patients with active disease fell to significantly lower levels when the disease had gone into remission after medical therapy. Serum DAF concentrations are increased in UC patients in relation to disease activity. The likely source of increased DAF concentrations is peripheral-blood leukocytes that have been activated as part of the UC disease process.

UR - http://www.scopus.com/inward/record.url?scp=1542506155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542506155&partnerID=8YFLogxK

U2 - 10.1016/j.lab.2003.11.004

DO - 10.1016/j.lab.2003.11.004

M3 - Article

C2 - 15007304

AN - SCOPUS:1542506155

VL - 143

SP - 152

EP - 158

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 3

ER -